A Study of Capravirine Plus VIRACEPT Plus Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients Who Failed Previous Anti-HIV Treatments

NCT00006211 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

350

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Capravirine
DRUG: Nelfinavir mesylate

Sponsor

Agouron Pharmaceuticals